Navigation Links
Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade

ENGLEWOOD, Colo., Nov. 2, 2011 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, has released a software upgrade for its ExactaMix® Automated Compounding Devices (ACD).  The new functionality includes 14 updates that provide Directors of Pharmacy with enhanced patient safety measures and features.

Hospital pharmacies worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) to compound large- and small-volume parenteral doses.  Baxa Corporation leads the ACD category with 65% of the global US market share, according to a recent poll in Pharmacy Purchasing & Products magazine.

Improved Efficiency, Added Safety Set Industry Standard

ExactaMix ACDs automatically compound multi-ingredient sterile doses, minimizing the risk of measurement errors, wrong drug selection, touch contamination and patient infection in the preparation of solutions for total parenteral nutrition (TPN), cardioplegia, dialysis and epidural delivery.  

To facilitate the upgrade, current ExactaMix customers will have one-on-one live installation support.  The ExactaMix software release includes the following key features for EM2400 and EM1200 users:

  • Water is now the default calibration ingredient for the US market.  The calibration source was redefined to allow multiple water calibration products.
  • The current patient formula is unloaded when the user exits the compounder screen, reducing the potential for the user to pump a wrong formula into the bag.
  • New priming process improves the purging of air bubbles in the inlets prior to pumping, enhancing the user prime process.
  • Integration with DoseEdge® Pharmacy Workflow Manager enables pharmacies to export MixCheck™ Report data for use with DoseEdge TPN.

State-of-the-art Baxa compounding technology delivers final bag accuracies within + 3% with barcode ingredient verification, and pumps a typical three-liter nutrition bag in approximately 3.5 minutes – nearly two times faster than the industry average.  ExactaMix provides volumetric delivery and gravimetric check with the ability to mix both micro and macro ingredients as low as 0.2 mL.  ExactaMix compounding efficiency enables pharmacy professionals to focus on patient care with the confidence that safety, regulatory compliance and preparation accuracy goals are met.

"The first company to offer automated compounding of both micro and macro ingredients in a single device, Baxa ACDs now serve over 20,000 patients daily across the globe," said Mark Miller, Product Manager at Baxa Corporation.  "In fact, 2012 marks the 10-year anniversary of doses compounded safely on the ExactaMix 2400 Compounder."

Baxa Corporation reliably and consistently enables pharmacists in more than 3,000 hospitals worldwide to safely prepare and administer intravenous therapies.  To learn more about the ExactaMix line of ACDs, visit  

For additional information on Baxa IV automation, to request a product brochure or download a free, educational white paper, visit, call 800.567.2292 or email

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging and administration of medications.  Key products used worldwide in hospitals and healthcare facilities include: the Abacus® Order Entry and Calculation Software, the DoseEdge® Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix® Automated Compounding Devices, InFuse™ and MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock® Set Saver and the RapidFill™ and IntelliFill® i.v. Automated Syringe Fillers.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at

Marian Robinson, Vice President, Marketing
Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157

Perrin McCormick
HB: 781-893-0053

SOURCE Baxa Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):